Cisplatin + Gemcitabine + Selumetinib
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
Conditions
Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
Trial Timeline
Oct 1, 2013 → Aug 1, 2014
NCT ID
NCT01949870About Cisplatin + Gemcitabine + Selumetinib
Cisplatin + Gemcitabine + Selumetinib is a phase 1 stage product being developed by AstraZeneca for Inoperable Locally Advanced or Metastatic Biliary Tract Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01949870. Target conditions include Inoperable Locally Advanced or Metastatic Biliary Tract Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01949870 | Phase 1 | Terminated |
Competing Products
10 competing products in Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin Mesylate | Eisai | Pre-clinical | 23 |
| Premetrexed (Alimta) + Carboplatin | Eli Lilly | Phase 1 | 33 |
| Fulvestrant + Capivasertib + Placebo | AstraZeneca | Phase 3 | 77 |
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Tomudex | AstraZeneca | Phase 2 | 52 |
| Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | AstraZeneca | Phase 3 | 77 |
| Drug (including placebo) | Merck | Phase 1 | 33 |
| BEZ235 + Paclitaxel | Novartis | Phase 1/2 | 41 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 41 |
| dacomitinib hydrate | Pfizer | Pre-clinical | 22 |